Molecular Prevalence and Risk Factors of Hepatitis B Virus Infection Among the Patients Attending the Human Medical Laboratories in Kabul, Afghanistan Hepatitis B in Kabul
Article Sidebar
Main Article Content
Abstract
Background: Hepatitis B virus (HBV) can cause acute and/or chronic hepatitis, responsible for over one million deaths annually. We aimed to estimate the prevalence of hepatitis B and its risk factors among the patients attending the Human Medical Laboratories (HML) in Kabul, Afghanistan.
Methods: This retrospective study was conducted on samples received between January 2022 and September 2023. We tested 2062 blood samples using a Geneproof Amplification Kit and Rotor-Gene Real-Time PCR. Descriptive and analytical statistics (Chi-square test and logistic regression) were analyzed using SPSS version 26.
Results: The prevalence of HBV was 51.2% (1056/2062), with 59.3% males and a mean (SD) age of 32.0 (14.9) years. The majority of the HBV-positive patients (792/1056 or 74.8%) were from the age group of 16–45 years. The highest and lowest prevalence of HBV was observed in Kandahar (29/48 or 60.4%) and Nangarhar (107/235 or 45.5%), respectively. The mean overall HBV viral load was 39,587,427.2 IU/mL, with the highest and lowest mean viral load observed in patients from Takhar (71,940,575.8 IU/mL) and Kandahar (1,419,819.0 IU/mL), respectively. The statistically significant risk factors associated with HBV were blood transfusion, dental extraction, and syringe sharing.
Conclusion: HBV is highly prevalent among the Afghans attending HML in Kabul, Afghanistan. The Afghanistan Ministry of Public Health and international donor agencies should help in conducting more studies of HBV in all 34 provinces of Afghanistan. This will help in finding the real burden and risk factors of HBV in different regions and ethnicities of Afghanistan.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
World Health Organization. World Health Organiza-tion. 2024 [cited 2025 July 5]. Hepatitis B. Availa-ble from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportuni-ties and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524–37.
World Health Organization. World Health Organiza-tion. 2024 [cited 2025 July 5]. Global hepatitis re-port 2024: action for access in low- and middle-income countries. Available from: https://www.who.int/publications/i/item/9789240091672
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken). 2018;12(1):33–4.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumals-wami P, Jacobson IM. Prevalence of Chronic Hepa-titis B Virus Infection in the United States. Am J Gastroenterol. 2020;115(9):1429–38.
Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, et al. Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. J Clin Transl Hepatol. 2021;9(2):143–8.
World Health Organization. World Health Organiza-tion. 2023 [cited 2025 July 5]. Afghanistan. Health data overview for the Islamic Republic of Afghani-stan. Population. Available from: https://data.who.int/countries/004
Essar MY, Siddiqui A, Head MG. Infectious diseases in Afghanistan: Strategies for health system im-provement. Health Sci Rep. 2023;6(12):e1775.
Behal R, Jain R, Behal KK, Bhagoliwal A, Aggarwal N, Dhole TN. Seroprevalence and risk factors for hepatitis B virus infection among general popula-tion in Northern India. Arq Gastroenterol. 2008;45(2):137–40.
Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis. 2007;11(4):685–706.
Redwan, NA, Ahmed, MMM, Barnawi, MBI. Preva-lence Study of Hepatitis B virus (HBV) Infection by Serological techniques in Jeddah, Saudi Arabia. Life Sci J. 2012;9(4):5442–8.
Lok ASF. Prevention of hepatitis B virus-related hepa-tocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S303-309.
Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vac-cination. Epidemiol Rev. 2006;28:112–25.
Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B vi-rus. Carcinogenesis. 2011;32(8):1122–32.
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68–76.
Wieland S, Thimme R, Purcell RH, Chisari FV. Ge-nomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A. 2004;101(17):6669–74.
Chisari FV, Isogawa M, Wieland. SF. Pathogenesis of hepatitis B virus infection. Pathologie Biologie. 2010;58(4):258–66.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45-55.
Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolv-ing epidemiology and implications for control. Semin Liver Dis. 1991;11(2):84–92.
André F. Hepatitis B epidemiology in Asia, the Mid-dle East and Africa. Vaccine. 2000;18 Suppl 1:S20-22.
Awan Z. Molecular prevalence of Hepatitis B virus infection in Khyber Pakhtunkhwa, Pakistan. Int J Med Med Sci. 2012;4(5):123–7.
Khan F, Shams S, Qureshi ID, Israr M, Khan H, Sarwar MT, et al. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. Virol J. 2011;8:225.
Nwokediuko SC. Risk Factors For Hepatitis B Virus Transmission In Nigerians: A Case-Control Study. Int J Gastroenterol [Internet]. 2009 [cited 2025 July 5];10(1). Available from: https://ispub.com/IJGE/10/1/11182
Zubair M, Anjum ZM, Zafar S, Shamaoon M, Balouch GR. Frequency of Hepatitis B Virus Infec-tion among Children with Chronic Liver Disease. Ann Punjab Med Coll. 2010;4(1):49–52.
Moosa FA, Shaikh BA, Choudhry MS, Zuberi BF, Khan FW, Sultan N. Frequency of hepatitis B and C in pre-operative patients for elective surgery. J Li-aquat Univ Med Health Sci. 2009;8(2):150–2.
Awan Z, Idrees M, Amin I, Butt S, Afzal S, Akbar H, et al. Pattern and molecular epidemiology of Hepa-titis B virus genotypes circulating in Pakistan. In-fect Genet Evol. 2010;10(8):1242–6.
Alam MM, Zaidi SZ, Malik SA, Shaukat S, Naeem A, Sharif S, et al. Molecular epidemiology of Hepa-titis B virus genotypes in Pakistan. BMC Infect Dis. 2007;7:115.
Usman HR, Akhtar S, Rahbar MH, Hamid S, Moattar T, Luby SP. Injections in health care settings: a risk factor for acute hepatitis B virus infection in Kara-chi, Pakistan. Epidemiol Infect. 2003;130(2):293–300.
Nazeer A, Ali S, Tipu I. Age-wise and Gender-wise Prevalence of Hepatitis B Virus (HBV) Infection in Lahore, Pakistan. BioSci Rev. 2019;1(4):20–8.
Jahani MR, Alavian SM, Shirzad H, Kabir A, Hajarizadeh B. Distribution and risk factors of hepa-titis B, hepatitis C, and HIV infection in a female population with “illegal social behaviour.” Sex Transm Infect. 2005;81(2):185.
Kurien T, Thyagarajan SP, Jeyaseelan L, Peedicayil A, Rajendran P, Sivaram S, et al. Community preva-lence of hepatitis B infection and modes of trans-mission in Tamil Nadu, India. Indian J Med Res. 2005;121(5):670–5.
Ghadir MR, Belbasi M, Heidari A, Jandagh M, Ah-madi I, Habibinejad H, et al. Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran. Hepat Mon. 2012;12(2):112–7.
Hayat A, Daud M, Shah SR, Shah H, Khattak Z, Wahab A. Serological prevalence of hepatitis B vi-rus infection in Lawaghar Valley, District karak KhyberPakhtoonkhwa, Pakistan. Int J Basic Med Sci Pharm. 2014;4(2):2049–4963.
Khan F, Akbar H, Idrees M, Khan H, Shahzad K, Kayani MA. The prevalence of HBV infection in the cohort of IDPs of war against terrorism in Ma-lakand Division of Northern Pakistan. BMC Infect Dis. 2011 June 20;11:176.
Fox, JA. Hepatitis B and the theatre nurse. Br J Thea-tre Nurs. 1996;6(7):26–9, 31.
Qureshi H, Arif A, Riaz K, Alam SE, Ahmed W, Mujeeb SA. Determination of risk factors for hepa-titis B and C in male patients suffering from chron-ic hepatitis. BMC Res Notes. 2009;2:212.
Zeeshan M, Shah M, Anwar F, Hamza M, Ali I, Ahmad H, et al. Chemiluminescent microparticle immunoassay-based detection on blood donor and incidence of HCV virus in district Mardan Pakistan. J Entomol Zool Stud. 2019;7(6):557–60.
Ahmad I, Warris D, Jabbar M, Shahab M, Hussain A, Fareed U, et al. Prevalence of Hepatitis B &C Virus with Respect to Different Age Groups in General Population of Bajaur Agency. Annals of R S C B. 2021;25(7):948–56.
Ziaee M, Zarban A, Malekinejad P, Akhbary H. Eval-uation of HGV Viremia Prevalence and Its Co-Infection with HBV, HCV, HIV and HTLV-1 in Hemophilic Patients of Southern Khorassan, Iran. Hepat Mon. 2007;7(1):11–4.
Eke AC, Eke UA, Okafor CI, Ezebialu IU, Ogbuagu C. Prevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virol J. 2011;8:12.
Li X, Zheng Y, Liau A, Cai B, Ye D, Huang F, et al. Hepatitis B virus infections and risk factors among the general population in Anhui Province, China: an epidemiological study. BMC Public Health. 2012;12:272.